Transgene SA, a company developing virus-based immunotherapies to treat cancer, has appointed James Wentworth as chief business officer and member of the executive management team. The appointment comes as Transgene advances a therapeutic vaccine for HPV-positive cancers. Dr Wentworth, who will lead business, corporate development and partnering strategies, has over 15 years of business development and commercial experience in pharma and biotech companies. He joined Transgene from Adaptimmune Plc where he was director, business development and strategy. Dr Wentworth holds a BSc and a PhD in pharmacology from the University of Bristol, UK, and an MBA from the International Institute for Management Development (IMD) in Lausanne, Switzerland.
Transgene announced the appointment on 22 January 2024.
Copyright 2024 Evernow Publishing Ltd